Overall, crizotinib presents itself as a promising targeted therapy across diverse cancer types by selectively inhibiting c-MET and ALK, leading to crizotinib’s accelerated approval by the US Food and Drug Administration (FDA) on 26 August 2011, for treating ALK+ locally advanced or metastatic NSCLC. This evidence concerns the gene MET and cancer.